clinical trials, more attention to the risk factors that can affect study results in this patient population, and validation of optical technologies that will provide valu- C ervical intraepithelial neoplasia (CIN), also known as cervical squamous intraepithelial lesions (SILs), provides an excellent model for various types of research, including chemoprevention trials. The natural history of cervical lesions has been well defined, 1 and the cervix is easily accessible, which makes histologic and pathologic studies more convenient than in other tissues. The progression of cervical lesions takes place over months to years. The Papanicolaou (Pap) smear is a well-known screening test for cervical cancer, and it can provide a cytologic model of disease progression. Cervical histopathology is one of the best validated models of CIN or SIL progression to cervical cancer. Colposcopy, which permits viewing the cervix through a mounted magnifying lens (called a colposcope) and using acetic acid as a contrast agent, provides a visual model of carcinogenic progression ( Figs. 1 and 2 ).
Chemoprevention Agents
Chemoprevention is defined as using micronutrients or pharmaceuticals to prevent or delay the development of cancer. Interest in micronutrients arose from the many epidemiological studies demonstrating that nutrient deficiencies existed in CIN cases but not in controls. Although many micronutrients have been tested (includ-ing folate, ␤-carotene, and vitamin C), none has produced a statistically significant regression of lesions in the treated group. 2 Several of these studies have been hampered by their design in that many of the micronutrients were not subjected to Phase I trial design controls meant to determine an effective dose or duration of use; therefore, the dose used in the Phase II study may not have been appropriate. 3, 4 Several pharmaceutical agents have appeared promising (Tables 1, 2) . Many of these pharmaceuticals have been tested in cell lines and animal models and have effectively suppressed the growth of cancerous or precancerous cells. In addition, because the carcinogenic role of the human papillomavirus (HPV) in cervical cancer has been established both in the field of molecular biology and epidemiology, many of these pharmaceuticals have been tested for their ability to suppress the production of viral oncoproteins. 28 A few of these agents have been subjected to rigorous Phase I study design. 3, 4 The only agent that has been demonstrated to cause regression of CIN/SILs in a randomized controlled trial in a statistically significant manner in a trial of sufficient sample size is topical all-trans-retinoic acid. 15 
Biomarkers, Vaccines, and Peptides
Although the field of cervical chemoprevention has yielded few successes, much has been learned regarding the carcinogenic process. Surrogate endpoint biomarkers serve as alternative endpoints for cancer incidence and are very helpful in determining the efficacy of chemopreventive agents. 2 The development and validation of these surrogate endpoint biomarkers is critically important to chemoprevention in other organ sites and, more important, in the development of new treatment strategies. Because HPV is a major etiologic agent, the measurement of HPV persistence and viral load should be considered as important as identifying biomarkers. Classes of surrogate endpoint biomarkers are listed in Table 3 . 28 Both vaccines and pharmaceuticals that suppress HPV are of interest. HPV vaccines are being developed following two strategies: preventive and therapeutic. 29, 30 Clinical trials of preventive vaccines aimed at creating antibody recognition of HPV capsid proteins are reported to be under way. 31 Similarly, clinical trials of therapeutic vaccines aimed at inducing cytotoxic T-cell recognition of HPV oncoproteins also are in progress. Both the prophylactic and therapeutic vaccines employ a number of strategies including viruslike particles, DNA vaccines, peptide vaccines, heatsensitive protein fusion vaccines, and chimeric virallike particle vaccines.
In addition to vaccines, there are other approaches to suppressing HPV, including immunomodulation and peptide drugs. There has been some success in the trial of prophylactic vaccines of viruslike particles. 32 The viral-like particle approach to prophylactic vaccines appears quite promising. Similarly, some success has been reported using therapeutic peptide vaccines.
Imiquimod, a topical agent, is an immune response modifier that is believed to induce local cytokines (including interferon-␣) to cause wart regression and currently is an accepted treatment for vulvar and vaginal warts. 33, 34 To our knowledge, no reports of randomized clinical trials of its use in the cervix have been published to date. Another compound, cidofovir, which is injected, is a peptide that suppresses viral expression and has been approved by the U.S. Food and Drug Administration as a treatment for laryngeal papillomatosis. [35] [36] [37] [38] Much of the validation of the surrogate endpoint biomarkers that has taken place in the field of chemoprevention can now be used to determine the success of vaccines, immunomodulators, and other antiviral agents. Similarly, many of the lessons learned from the study design of cervical chemoprevention trials can be applied so that the clinical trials of these agents can proceed more quickly. Rigorous attention must be paid to duration of use, dosage, and method of followup. Investigators need to be cognizant of risk factors that may modify a patient's response to treatment. Although the best strategy is to stratify patients in the trial by these risk factors at the time of study entry, researchers should at least take these risk factors into account when analyzing response. These include the nutritional status of the patient, smoking status, recurrent as opposed to incident disease, use of hormonal contraception, immunocompetence (human immunodeficiency virus, organ transplantation, connective tissue disorders, or other autoimmune disorders), age, and menopausal status.
Future Directions
Optical technologies may provide a novel biomarker of disease progression and regression. These technologies include such strategies as fluorescence and reflectance spectroscopy, optical coherence tomography, and confocal imaging, which provide real-time information regarding the redox ratio, chromatin distribution, and the nuclear-to-cytoplasmic ratio. An illustration of redox potentials in cervical tissue is shown in Figure 3 . Once validated, optical biomarkers could help monitor disease regression, persistence, or progression in patients in real time without biopsy. Although there is much to be done in the development of these optical technologies to validate their use, they provide an exciting opportunity to obtain quantitative information in real time at each visit. Because biopsy itself induces regression, the use of these optical technologies would allow investigators to monitor patients safely throughout clinical trials of these new agents. Optical contrast agents, which target biomarkers, also will provide a novel method of gathering molecular biologic data quantitatively and reproducibly throughout a trial. Optical contrast agents could be designed specifically for HPV or other immunologic or molecular biologic targets that are associated with increased progression of disease. Some of the new research directions in chemoprevention and vaccine development that were mentioned in discussion included using a transgenic mouse model to test and validate new compounds and conducting Phase I clinical trials of nonsteroidal antiinflammatory drugs. The need for a clinical trial of indole-3-carbinol (with background studies of the role of estrogen in HPV integration, persistence, and expression) also was discussed, as was the need for well-designed vaccine trials in general. The development of immunologic surrogate endpoint biomarkers was another research area mentioned that needs exploring, as do well-designed trials of immunomodulators such as imiquimod and peptide drugs such as cidofovir. Finally, using optical technologies as new biomarkers in randomized clinical trials was discussed as a tool for monitoring chemoprevention and vaccine studies. 
